Free Trial

Relay Therapeutics (RLAY) Stock Forecast & Price Target

$8.24
+0.48 (+6.19%)
(As of 07/12/2024 ET)

Relay Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$22.80
176.70% Upside
High Forecast$30.00
Average Forecast$22.80
Low Forecast$15.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$22.80$22.80$23.69$26.28
Forecasted Upside176.70% Upside198.66% Upside108.41% Upside108.92% Upside
Get Relay Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

RLAY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RLAY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Relay Therapeutics Stock vs. The Competition

TypeRelay TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.71
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside176.70% Upside994.16% Upside9.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/7/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00+175.10%
5/10/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$15.00 ➝ $15.00+137.72%
5/6/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$24.00+247.83%
5/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $25.00+255.11%
2/22/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/22/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$25.00 ➝ $30.00+181.69%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
4/20/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Hold$16.00 ➝ $12.50+1.21%
4/19/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$42.00 ➝ $29.00+134.82%
4/19/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeOutperform ➝ Strong-Buy$29.00+149.57%
3/9/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$45.00 ➝ $28.00+65.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:42 AM ET.

RLAY Forecast - Frequently Asked Questions

What is Relay Therapeutics' forecast for 2024?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Relay Therapeutics is $22.80, with a high forecast of $30.00 and a low forecast of $15.00.

Should I buy or sell Relay Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RLAY shares.

Does Relay Therapeutics's stock price have much upside?

According to analysts, Relay Therapeutics's stock has a predicted upside of 198.66% based on their 12-month stock forecasts.

Has Relay Therapeutics been upgraded by Wall Street analysts recently?

Over the previous 90 days, Relay Therapeutics's stock had 1 upgrade by analysts.

What analysts cover Relay Therapeutics?

Relay Therapeutics has been rated by research analysts at Barclays, HC Wainwright, JMP Securities, and Oppenheimer in the past 90 days.

Do Wall Street analysts like Relay Therapeutics more than its competitors?

Analysts like Relay Therapeutics more than other "medical" companies. The consensus rating for Relay Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RLAY compares to other companies.


This page (NASDAQ:RLAY) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners